| Ytd | -47.92% | |
| 1y | -50.11% |
| Open | 9.21 | Prev Close | 9.36 | Low | 9.00 | High | 9.33 | Mkt Cap | 508.52M |
| Vol | 217.63K | Avg Vol | 851.70K | EPS | -6.25 | P/E | N/A | Forward P/E | -10.51 |
| Beta | N/A | Short Ratio | 5.58 | Inst. Own | 56.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 11.81 | 200-d Avg | 21.29 | 1yr Est | 41.50 |
MPLT News
Award honors foundational discoveries in optogenetics and circuit mapping These discoveries laid the
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the
MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on imp
UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r
Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Bu
Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT)
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dos
Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg B
UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the
BMO Capital analyst Malcolm Hoffman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) wit
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the
Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with
Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowe
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements
The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses plann
Stifel analyst Paul Matteis maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises t
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MapLight Therapeutics (NASDAQ:MPLT)
UBS analyst Ashwani Verma initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy ra
Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(1.34) per share which missed the
Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See an
Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, includ
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on MapLight Therapeutics (N
The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluatin
Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis,
Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrad
Needham analyst Ami Fadia initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy ra
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(2.47) per share which missed the
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on MapLight Therapeutics (NASDAQ:MPL
In a Phase 1 clinical trial, ML-007C-MA demonstrated a generally favorable safety and tolerability p
SandboxAQ and MapLight Therapeutics, Inc. (NASDAQ:MPLT) announced today that the companies have ente
